Shane Cooke Biography and Net Worth

Director of Alkermes

Mr. Cooke served as President of Alkermes from September 2011 until his retirement in March 2018. He became a Director of Alkermes upon his retirement. Mr. Cooke is Chairman of the Board of Alkermes Pharma Ireland Limited (“APIL”), a wholly-owned subsidiary of Alkermes, and has held that position since September 2011. From May 2007 to September 2011, Mr. Cooke was Executive Vice President of Elan Corporation, plc (“Elan”) and Head of Elan Drug Technologies. He served as the Chief Financial Officer of Elan from July 2001, when he joined Elan, until May 2011. From May 2005 to September 2011, Mr. Cooke served as a Director of Elan. Prior to joining Elan, he was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that, held a number of senior positions in finance in the banking and aviation industries. Mr. Cooke is a chartered accountant and currently sits on the Boards of Directors of Prothena Corporation plc and Endo International plc.

What is Shane M. Cooke's net worth?: The estimated net worth of Shane M. Cooke is at least $41,299.72 as of September 28th, 2022. Mr. Cooke owns 1,219 shares of Alkermes stock worth more than $41,300 as of March 26th. This net worth evaluation does not reflect any other assets that Mr. Cooke may own. Learn More about Shane M. Cooke's net worth.
How do I contact Shane M. Cooke?: The corporate mailing address for Mr. Cooke and other Alkermes executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. Alkermes can also be reached via phone at (531) 772-8000 and via email at investor_relations@alkermes.com. Learn More on Shane M. Cooke's contact information.
Has Shane M. Cooke been buying or selling shares of Alkermes?: Shane M. Cooke has not been actively trading shares of Alkermes during the past quarter. Most recently, Shane Cooke sold 10,000 shares of the business's stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $29.23, for a transaction totalling $292,300.00. Following the completion of the sale, the director now directly owns 90,478 shares of the company's stock, valued at $2,644,671.94. Learn More on Shane M. Cooke's trading history.
Who are Alkermes' active insiders?: Alkermes' insider roster includes Emily Alva (Director), David Anstice (Director), Iain Brown (CFO), Shane Cooke (Director), Wendy Dixon (Director), David Gaffin (SVP), Craig Hopkinson (EVP), Blair Jackson (COO), Michael Landine (SVP), Cato Laurencin (Director), Christian Nichols (SVP), Richard Pops (Chairman & CEO), and Nancy Wysenski (Director). Learn More on Alkermes' active insiders.
Are insiders buying or selling shares of Alkermes?: During the last year, insiders at the sold shares 8 times. They sold a total of 393,075 shares worth more than $12,938,532.90. The most recent insider tranaction occured on February, 13th when EVP Craig C Hopkinson sold 144,419 shares worth more than $5,131,207.07. Insiders at Alkermes own 4.9% of the company. Learn More about insider trades at Alkermes.
Information on this page was last updated on 2/13/2025.

Shane M. Cooke Insider Trading History at Alkermes

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/2/2022	Sell	10,000	$29.23	$292,300.00	90,478
4/25/2022	Sell	10,000	$27.88	$278,800.00	90,478
4/18/2022	Sell	10,000	$28.88	$288,800.00	90,478
4/11/2022	Sell	10,000	$29.26	$292,600.00	90,478
4/4/2022	Sell	10,000	$28.18	$281,800.00	90,478
2/2/2018	Sell	72,793	$60.55	$4,407,616.15	147,501
1/29/2018	Sell	3,300	$60.00	$198,000.00	76,408
1/26/2018	Sell	1,700	$60.02	$102,034.00	76,408
1/11/2018	Sell	6,207	$60.22	$373,785.54	80,915
6/8/2017	Sell	10,000	$60.33	$603,300.00	84,708
5/4/2017	Sell	6,500	$60.05	$390,325.00	78,448
3/29/2017	Sell	2,070	$60.00	$124,200.00	72,148
3/23/2017	Sell	6,030	$60.01	$361,860.30	74,948
3/21/2017	Sell	1,900	$60.09	$114,171.00	72,048
3/20/2017	Sell	300	$60.00	$18,000.00	72,048
3/2/2017	Sell	20,000	$60.00	$1,200,000.00	73,068
1/9/2017	Sell	550	$60.27	$33,148.50	64,494
1/6/2017	Sell	9,450	$60.06	$567,567.00	66,487
12/23/2015	Sell	18,000	$77.23	$1,390,140.00	50,240
11/23/2015	Sell	18,000	$72.62	$1,307,160.00	50,240
10/23/2015	Sell	18,000	$62.03	$1,116,540.00	50,240
9/23/2015	Sell	18,000	$67.09	$1,207,620.00	40,640
8/24/2015	Sell	18,000	$57.65	$1,037,700.00	40,640
7/23/2015	Sell	18,000	$69.79	$1,256,220.00
6/23/2015	Sell	18,000	$66.84	$1,203,120.00
5/26/2015	Sell	18,000	$60.31	$1,085,580.00
4/23/2015	Sell	18,000	$62.55	$1,125,900.00
3/23/2015	Sell	18,000	$65.33	$1,175,940.00
2/23/2015	Sell	18,000	$74.29	$1,337,220.00
1/23/2015	Sell	118,000	$69.13	$8,157,340.00

See Full Table

Shane M. Cooke Buying and Selling Activity at Alkermes

Alkermes Company Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Today's Range

Now: $33.88

$33.71

$34.89

50 Day Range

MA: $33.21

$29.05

$36.00

2 Week Range

Now: $33.88

$22.90

$36.45

Volume

1,407,682 shs

Average Volume

1,696,869 shs

Market Capitalization

$5.51 billion

P/E Ratio

15.61

Dividend Yield

N/A

Beta

0.62